AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Infudopa SubC Parkinsons Therapy: Neuraxpharm-Dizlin Deal

Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company...

China Unveils Innovative Drugs Policy to Boost Development

The National Health Commission and China's National Healthcare Security...

HALEON APPOINTS CARL HANEY AS CHIEF R&D OFFICER

Haleon today announces the appointment of Carl Haney as...

AbbVie Inc. and Tentarix Biotherapeutics today announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology. The collaboration will integrate AbbVie’s expertise in oncology and immunology with Tentarix’s proprietary Tentacles™ platform.

Tentacles™ are multi-functional, conditionally-active antibody-based biologics that are designed specifically to activate immune cells that can modulate disease pathways, while potentially mitigating safety concerns associated with non-specific targeting of other immune cells.

“Oncology and immunology are two of our key strategic growth areas where we are pursuing novel technologies that aim to deliver transformative therapies, which address unmet patient needs,” said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie. “This strategic partnership complements our ongoing efforts in developing novel biologics, potentially to expand our oncology and immunology portfolios with conditionally-active multi-specific molecules.”

“We are excited to join forces with AbbVie to help accelerate cutting-edge, conditionally-active therapeutic programs towards clinical applications for patients in need,” said Don Santel, interim chief executive officer, Tentarix Biotherapeutics. “This collaboration adds to our portfolio of internal and external pipeline programs and is a strong validation of our approach in understanding and targeting complex immune interactions that drive cancers and inflammatory diseases.”

Under the terms of the agreements, Tentarix will receive upfront option payments, totaling $64 million from AbbVie, for the two programs. AbbVie will receive an exclusive option to fully acquire the programs following candidate nomination, for an additional undisclosed payment for each program.

Latest stories

Related stories

Infudopa SubC Parkinsons Therapy: Neuraxpharm-Dizlin Deal

Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company...

China Unveils Innovative Drugs Policy to Boost Development

The National Health Commission and China's National Healthcare Security...

HALEON APPOINTS CARL HANEY AS CHIEF R&D OFFICER

Haleon today announces the appointment of Carl Haney as...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back